eToro - Investment and Trading Platform Home Page
SearchSearch
Languages
Language
LoginSign up
Login
Stocks-PHAT-Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc PHAT

$11.85-0.33(-2.71%)(1D)
• Delayed prices by Nasdaq • in USD
Invest in Phathom Pharmaceuticals Inc
Today
Create an eToro account to buy PHAT stock on a secure, user-friendly, multi-asset trading platform.
Buy Phathom Pharmaceuticals Inc
Buy Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals Inc PHAT
Buy PHAT
Analyst Forecast
i
This 12-month forecast is based on a composite of analyst projections. Based on analysts with a rating of 4+ stars. This is not a prediction made by eToro nor is it investment advice.
Consensus
Strong Buy
Price Target
21.83
Based on analysts who covered PHAT

Trending stocks

See stocks with the biggest daily volume spikes vs. their 3-month average.

Phathom Pharmaceuticals Inc News

About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals Inc is an advanced clinical-stage biopharmaceutical company engaged in the development and commercialisation of treatments for gastrointestinal diseases. The company has a broad operational footprint that focuses primarily on the US market.

Operating in the competitive biotechnology sector, Phathom Pharmaceuticals Inc distinguishes itself by focusing on diseases of the gastrointestinal tract. Its main product candidate, Vonoprazan, is designed to address unmet needs tied to diseases involving stomach acid. The company operates autonomously but maintains a strategic collaboration with Takeda Pharmaceutical Company Limited.

Track the share price of PHAT by adding it to your eToro watchlist.
VIEW MORE   

PHAT Stock Price Chart

‎42.53‎
Past Month
1D
1W
1M
6M
1Y
3Y
MAX
Sign up for full charts powered byTradingView logo
*Past performance is not an indication of future results
Asset negative trend

The Phathom Pharmaceuticals Inc share price is on the decline this week.

i
A ‘rising’ price indicates that the weekly price has increased by more than 0.5%.
A price ‘on the decline’ indicates that the weekly price has decreased by more than 0.5%.
A ‘stable’ price indicates that the change in weekly price is between -0.5% and 0.5%.
The Phathom Pharmaceuticals Inc share price today is $11.85, reflecting a ‎-2.71‎% change over the last 24 hours and ‎-4.90‎% over the past week. The current market capitalization of PHAT is $840.68M with an average volume in the last three months of 2.29M. The stock has a P/E ratio of -2.51 and a dividend yield of 0%. With the stock’s beta sitting at 1.19
Market Cap
i
Total value of all asset shares, calculated by multiplying the price by the total number of outstanding shares.
$840.68M
Day’s Range
i
Shows the high and low prices of the day.
$11.69 - $12.21
52W Range
i
Shows the high and low prices of the last year.
$2.2 - $19.61
Average Volume (3M)
i
The average number of shares traded per day over the last three months.
2.29M
Price-Earnings Ratio
i
The result of this asset’s share price divided by its earnings per share.
-2.51
Revenue
i
The total income generated by this company’s goods and services last year.
$114.04M
Dividend (Yield)
i
How much a company pays out in dividends each year relative to its stock price.
$0 (0%)
Prev Close
i
The final price of this asset at the end of the last trading day.
$11.85
EPS
i
A company’s total earnings divided by the number of shares it has issued.
$-4.73
Beta
i
A measure of whether any asset does, or doesn’t, experience price moves in line with the broader market.
1.19
What Is Phathom Pharmaceuticals Inc?
Phathom Pharmaceuticals Inc is an advanced clinical-stage biopharmaceutical company engaged in the development and commercialisation of treatments for gastrointestinal diseases. The company has a broad operational footprint that focuses primarily on the US market.

Operating in the competitive biotechnology sector, Phathom Pharmaceuticals Inc distinguishes itself by focusing on diseases of the gastrointestinal tract. Its main product candidate, Vonoprazan, is designed to address unmet needs tied to diseases involving stomach acid. The company operates autonomously but maintains a strategic collaboration with Takeda Pharmaceutical Company Limited.

Track the share price of PHAT by adding it to your eToro watchlist.
CEO
Steven L. Basta, MBA
Employees
427
Founded
2018
HQ
Florham Park, New Jersey, US
Med Tech
NASDAQ
Buy PHAT

How can I buy Phathom Pharmaceuticals Inc stocks?

To purchase Phathom Pharmaceuticals Inc:
01

Create an eToro account:

Sign up for an eToro account and verify your identity.
02

Deposit funds:

Deposit funds into your eToro account using your preferred payment method.
03

Search and purchase:

Search the Phathom Pharmaceuticals Inc (PHAT) page and place an order to buy Phathom Pharmaceuticals Inc.
Buy PHAT
Looking for more information? Check out our guide on Academy.
Top Guides
Our top picks for the most relevant guides from the eToro Academy
Top Dividend Stocks for 2025
Top Dividend Stocks for 2025
Gear up for 2025 with these top dividend stocks. Dive into the potential of Verizon, Exxon Mobil, NextEra, Coca Cola, Unicredit through eToro’s expert analysis.
Read More
Stock Trading And Investing For Beginners
Stock Trading And Investing For Beginners
New to online trading? Learn the basics with eToro. What are stocks? trading vs. investing, what are the risks, and how to open a trade, step by step.
Read More
AI Stocks Poised for Growth in 2025
AI Stocks Poised for Growth in 2025
Gear up for 2025 with AI stocks. Dive into the potential of Nvidia, Broadcom, CrowdStrike, Arista Networks, and Amphenol, through eToro’s expert analysis.
Read More
Go to the Academy >
Graph
Buy Phathom Pharmaceuticals Inc
Invest in Phathom Pharmaceuticals Inc
Today
Create an eToro account to buy PHAT stock on a secure, user-friendly, multi-asset trading platform.
Buy PHAT

FAQ

The current price of PHAT is $11.85.
The average price target for Phathom Pharmaceuticals Inc is $21.83. Sign up to eToro for detailed analyst forecasts and price targets.
Analysts offer forecasts for Phathom Pharmaceuticals Inc based on market trends, financial reports and projected growth. Check the latest forecast for future price movements.
The market capitalisation of Phathom Pharmaceuticals Inc is $840.68M
Based on 6 analysts offering recommendations for PHAT in the last 3 months, the overall consensus is Strong Buy.
Daily Movers
Explore the biggest stocks movers on the market.
English (UK)Check icon
Deutsch
Français
Polski
Português
Dansk
Suomi
Español
Русский
العربية
Nederlands
Svenska
Română
Italiano
中文
繁體中文
Norsk
Čeština
Tiếng Việt
Scroll to top